Tuberculosis Therapeutics Market Report 2026

Tuberculosis Therapeutics Market Overview

• Tuberculosis Therapeutics market size has reached to $2 billion in 2025 • Expected to grow to $2.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.1% • Growth Driver: Impact Of Rising TB-HIV Co-Infection Rates On The Growth Of The Market • Market Trend: Advancements In Tuberculosis Therapeutics For Drug Resistance • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tuberculosis Therapeutics Market?

Tuberculosis therapeutics refers to the pharmaceutical treatments designed to prevent and cure tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. The purpose of these therapeutics is to eradicate the bacteria, reduce transmission, and improve patient outcomes, particularly for those with drug-resistant strains. The main types of tuberculosis therapeutics are active tuberculosis (tb) and latent tuberculosis (tb). Active tuberculosis (TB) is a contagious bacterial infection caused by Mycobacterium tuberculosis that primarily affects the lungs, causing symptoms like persistent cough, fever, and weight loss. There are different product types available, like isoniazid, rifampin, pyrazinamide, hydrazine derivatives, miscellaneous anti-tubercular drugs, and ethambutol. Its routes of administration types are oral, parenteral, and others, and they are distributed through various channels such as hospital pharmacy, retail pharmacy, and online pharmacy and are used by several end users, including hospitals, clinics, ambulatory surgical centers, and others.

What Is The Tuberculosis Therapeutics Market Growth Forecast?

The tuberculosis therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to growing prevalence of multidrug-resistant tb, advancements in novel tb drug development, increasing global health funding, expansion of digital adherence technologies, rising focus on preventive tb treatment. Major trends in the forecast period include increasing development of drug-resistant tb therapies, rising adoption of combination treatment regimens, growing focus on shorter treatment durations, expansion of public health tb programs, improved patient adherence monitoring.

Global Tuberculosis Therapeutics Market Segmentation

1) By Type: Active Tuberculosis (TB), Latent Tuberculosis (TB) 2) By Drug Type: Isoniazid, Rifampin, Pyrazinamide, Hydrazine derivatives, Miscellaneous anti-tubercular drugs, Ethambutol 3) By Route of Administration: Oral, Parenteral, Other route of administration 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users Subsegments: 1) By Active Tuberculosis (TB): First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol), Second-Line Drugs (Fluoroquinolones, Aminoglycosides), Combination Therapies, Drug-Resistant TB Treatments (MDR-TB, XDR-TB) 2) By Latent Tuberculosis (TB): Isoniazid Prophylaxis, Rifampicin-Based Regimens, Rifapentine-Based Regimens, Combination Prophylactic Therapies

What Is The Driver Of The Tuberculosis Therapeutics Market?

Rising co-infection rates of tuberculosis (TB) and human immunodeficiency virus (HIV) are expected to propel the growth of the tuberculosis therapeutics market going forward. Co-infection rates (TB-HIV) refer to the prevalence of individuals simultaneously infected with both TB and HIV an interaction that complicates diagnosis, treatment, and patient outcomes due to immune suppression and overlapping epidemics. The increase in these co-infections drives demand for combined therapeutic approaches that target TB infection within HIV-positive populations, improving overall outcomes and reducing the burden of both diseases. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, the number of tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, representing a rise of 1,295 cases. Therefore, rising TB-HIV co-infection rates are driving the growth of the tuberculosis therapeutics industry.

Key Players In The Global Tuberculosis Therapeutics Market

Major companies operating in the tuberculosis therapeutics market are Pfizer Inc, Johnson & Johnson, Roche Holding AG, Merck & Co. Inc, Sanofi S.A, Novartis AG, GlaxoSmithKline plc, Viatris Inc, Cipla Limited, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Sequella Inc, AstraZeneca plc, Eli Lilly and Company, Biofabri S L, LegoChem Biosciences, BioVersys AG, SENTAN Pharma Inc, ViChem Pharmaceuticals Inc, PDS Biotechnology Corporation, BioNTech SE, Qurient Co Ltd

Global Tuberculosis Therapeutics Market Trends and Insights

Major companies operating in the tuberculosis therapeutics market are focusing on developing innovative solutions, such as combination therapy, to improve treatment efficacy, reduce the duration of therapy, and combat drug-resistant strains of tuberculosis. Combination therapy refers to the use of two or more medications from different classes to treat a disease, aiming to increase treatment efficacy, reduce resistance, and improve patient outcomes. For instance, in July 2024, Johnson & Johnson, a US-based pharmaceutical company, achieved a significant milestone in tuberculosis treatment with the approval of SIRTURO (bedaquiline) by both the U.S. FDA and the European Commission. This innovative drug is the first in over four decades specifically designed to target multidrug-resistant tuberculosis (MDR-TB). Its unique mechanism of action, inhibiting the ATP synthase enzyme essential for TB bacteria's energy production, thereby offering a targeted and effective therapeutic approach. Its inclusion in combination therapies enhances the overall efficacy of MDR-TB regimens, reducing treatment duration and improving patient compliance.

What Are Latest Mergers And Acquisitions In The Tuberculosis Therapeutics Market?

In May 2024, BioVersys AG, a Switzerland-based biotechnology company, partnered with GSK plc. Through their strategic collaboration, GSK and BioVersys intend to expedite the clinical advancement of alpibectir (BVL-GSK098) for the treatment of tuberculosis (TB). GSK plc is a UK-based pharmaceutical company that focuses on the development and manufacture of innovative medicines, including tuberculosis (TB) therapeutics.

Regional Outlook

North America was the largest region in the tuberculosis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Tuberculosis Therapeutics Market?

The tuberculosis therapeutics market consists of sales of combination therapies, vaccines, supportive therapies, biologics, and newer drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tuberculosis Therapeutics Market Report 2026?

The tuberculosis therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tuberculosis therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.